Mar 30, 2021

Featuring an interview with Dr Roberto Iacovelli on the following topics:

• New hormonal therapies for prostate cancer (0:00)
• Risk of cardiovascular adverse events with new hormonal therapies for prostate cancer (2:45)
• Metabolic syndrome related to new hormonal therapies for prostate cancer (9:50)
• Bone fractures with androgen deprivation therapy (ADT) and new hormonal therapies for prostate cancer (13:30)
• Central nervous system toxicities and other adverse effects associated with new hormonal therapies for prostate cancer (17:14)
• Case: A man in his early 70s with metastatic castration-sensitive prostate cancer and a history of arterial hypertension (21:47)
• Case: A man in his early 60s with metastatic castration-sensitive prostate cancer and a history of rheumatoid arthritis, arterial hypertension and hepatitis C infection (26:55)
• Case: A man in his late 70s with nonmetastatic castration-resistant prostate cancer and a history of arterial hypertension (29:59)

CME information and select publications